Figure 3. Treatment Effect of Dapagliflozin on the Primary Composite Outcome by Timing of Most Recent Heart Failure (HF) Hospitalization Relative to Trial Enrollment.

Patients with a more recent hospitalization for HF experienced robust relative and absolute risk reductions in the primary efficacy outcome of cardiovascular death or worsening heart failure. ARR indicates absolute risk reduction; HR, hazard ratio.